TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Hua-Yi Jun, Phd) · huayj@sysucc.org.cn · 18820019088

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · PD-1 · Surgery

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China · Guangzhou, China

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Recurrent or Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China · Guangzhou, China

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma · High-Risk Cancer · Maintenance Therapy

Abroad (travel likely)RecruitingPHASE3

Ganzhou, China · Guangzhou, China

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma · Laryngeal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Orange, United States